Alex is a Cofounder and CEO of Diagonal Therapeutics and an Entrepreneur-in-Residence in Atlas Venture. During his 20+ year career in biotechnology, he served as COO of Dragonfly Therapeutics, CDO of Morphic Therapeutic, VP of Therapeutics at Merrimack Pharmaceuticals, and Associate Director of Drug Discovery at Biogen. Alex is an author of over 100 patents and manuscripts. He is an Associated Editor of the mAbs and serves on the Board of Directors of the Antibody Society. He has received an Advanced Certificate for Executives in Management, Innovation and Technology from MIT Sloan School of Management, a Ph.D. in Biophysics from Harvard University, an M.Sc. in Molecular Biophysics, and a B.Sc. in Mathematics and Physics from the Moscow Institute of Physics and Technology.

 Alex holds a PhD degree in computational chemistry and MBA from Mannheim Business School. Alex brings more than 10 years of experience in the biotech space, being a co-founder of drug development startup himself and then moving to the VC side. He successfully invested in Biotech and Medtech startups from a VC fund RBV Capital and from CVC arm of tier 1 reinsurance company SCOR.

Rob is a cofounder of London-based Hoxton Ventures and is currently cofounding  H Tree Capital, a specialized seed tech:bio fund. He has over thirteen years in the VC industry and was previously a product manager at Google in Silicon Valley. He holds a degree in Computer Science from the University of Maryland. His notable investments include Babylon Health, Preply, Spacelift.io and several dozen others.

Hoxton Ventures is an early stage venture capital firm based in London and investing in European technology startups that can scale into large, global winners. It focuses on startups that either disrupt existing industries or invent entirely new market categories. It was the first institutional investor in Babylon Health, Darktrace and Deliveroo, and its portfolio companies have grown to an aggregate value of over $32 billion. Hoxton typically invests between $500,000 and $5 million into pre-seed and seed stage companies, and follows its capital through the life of the company. For more information please visit https://www.hoxtonventures.com.

Georgia is passionate about working closely with startup founders to realize their vision through focused development, operations and fundraising resource and strategies. A seasoned M&A professional, Georgia has a deep network of corporate and institutional investors to leverage in order to help early stage companies scale.

Georgia is the founding partner of Magnet Ventures, seed investor and board member of INNFOS (exited), investor of Cloudminds (exited), seed investor of AI-Biotech companies: Valink Therapeutics (formerly LiliumX), Flux Biosciences, Regard (formerly HealthTensor), Atom Bioworks.

Charles Conn is a seasoned business builder and investor. Before co-founding Monograph Capital, a life sciences venture firm, he was CEO of Oxford Sciences Innovation, a £600m deep science venture firm formed in partnership with Oxford. Charles is a technology entrepreneur and former public company CEO (Ticketmaster/Citysearch/Match.com).

He serves as Chair of Patagonia, and was previously CEO of the Rhodes Trust; before that he was senior advisor to the Gordon & Betty Moore Foundation. He began his career at McKinsey & Company, where he was a Partner. He is a graduate of Harvard Business School, Boston University, and Oxford University, where he was a Rhodes Scholar.

Innovative strategy, partnerships and market shaping executive with 15+ years of leadership experience in U.S., European, and global healthcare environments (NCDs, neuro, onco). Proven record of designing and executing strategies that simultaneously shape commercial and reputational ambition; driving high-impact campaigns that catalyze healthcare system changes; and fomenting large-scale partnerships that connect the dots between influential stakeholders and improved patient outcomes. Yale Ph.D, Fulbright Scholar, former NIH/WHO, and trade group veteran with deep networks across UN, EU and US political, academic, and health tech spheres.

Known for creative, high-impact campaigns that underpin P&R decisions; and driving innovative partnerships that address health disparities, particularly between pharma and tech.

Jose has over 10 years’ experience in antibody discovery and preclinical development in biotech and pharma. Jose is currently Director, Lead Adaptate Pre-Clinical at Takeda, where he is responsible for progressing programmes from discovery through clinical development. He was previously at F-star Therapeutics where he led immune cell engager programmes from inception to pre-IND, and beyond into Phase I, spanning multiple internal and external drug candidates, publications, and patents. He also held key platform, technology, and pharmacology development roles within F-star.

Before joining Adaptate (acquired by Takeda), Jose also held other scientific roles within AstraZeneca and Cambridge Antibody Technology. Jose has a very keen interest in multispecific antibodies and multifunctional proteins, and the possibilities this type of drugs hold in addressing areas of highly unmet clinical needs.

Keith Mostov is a Professor of Cell Biology, Biochemistry and Biophysics at the University of California, San Francisco (UCSF). He also founded or co-founded several biotech companies, including Novellus DX. Prof. Mostov was a Rhodes Scholar, received his MD from Weil-Cornell Medical College and PhD with Nobel Laureate Guenter Blobel at The Rockefeller University.

Subsequently, he was a Whitehead Fellow and Principal Investigator at the Whitehead Institute, before moving to UCSF. He has worked on polymeric immunoglobulins, as well as epithelial polarity and morphogenesis.